Michigan Clinical Trials Report — April 2026

For Michiganders considering participation in medical research, April 2026 presents a critical window of opportunity, especially for those looking to join studies that are nearing their enrollment deadlines. Across the state, a significant number of trials are slated to close soon, with 150 studies concluding within the next 90 days. This urgency extends to healthy volunteers, as 15 of these rapidly closing studies are actively seeking participants without specific health conditions. Individuals interested in contributing to medical advancements should explore these options promptly before they are no longer available.

Impending Deadlines: Act Now for Critical Studies

The approaching deadlines mean that patients managing certain health conditions have a limited time to enroll in ongoing research. Trials focused on specific types of cancer, neurological conditions, and inflammatory diseases are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Breast cancer (4 trials)
• Advanced solid tumor (3 trials)
• Focal epilepsy (2 trials)
• Atrial fibrillation (2 trials)
• Esophageal cancer (2 trials)
• Fibromyalgia (2 trials)
• Acute lymphoblastic leukemia (2 trials)
• Asthma (2 trials)
• Acute myeloid leukemia (2 trials)
• Atopic dermatitis (2 trials)

With 15 opportunities for healthy volunteers closing within the next three months, individuals without specific medical conditions have a chance to contribute to foundational research. These studies are crucial for establishing baseline data and understanding how new treatments affect the general population. If you've been considering participating, now is the time to act.

Michigan's Research Horizon: Notable New Trials in April

This month, Michigan saw the opening of 14 new clinical trials, a decrease from the 30 trials that launched in March 2026. Despite this dip, the state continues to offer a diverse array of cutting-edge research opportunities, with a total of 2,138 clinical trials currently recruiting across 123 cities and 1,301 research sites statewide.

Several high-profile new trials from major pharmaceutical companies and leading academic institutions have launched, offering participants the chance to engage with innovative treatments and diagnostic tools. These studies address a range of health challenges, from metabolic disorders and various cancers to autoimmune conditions and psychological distress.

• Novartis Pharmaceuticals is sponsoring NCT07517263, "An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)." This Phase 3 open-label extension study will provide post-trial access to pelacarsen (TQJ230) for participants who have successfully completed the double-blind parent study, aiming for 5,700 participants.
• The University of Michigan Rogel Cancer Center is leading NCT07526545, the "Urine Prostate Screening Integrated With MRI for Early Detection of Prostate Cancer, UPRISE Trial." This trial tests how well a urine prostate cancer screening test, My Prostate Score 2 (MPS2), integrated with magnetic resonance imaging (MRI) works for early detection of prostate cancer, targeting 800 participants.
• Memorial Sloan Kettering Cancer Center is sponsoring NCT07507643, "A Study of Methylprednisolone in People Having Liver Surgery." This Phase 3 study aims to test whether receiving methylprednisolone before surgery will reduce side effects like infections and longer hospital stays for 750 participants.
• Incyte Corporation is sponsoring NCT07522073, "A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma." This Phase 3 study will evaluate the efficacy and safety of standard chemotherapy with or without INCB161734 in participants with metastatic pancreatic ductal adenocarcinoma (PDAC), involving 588 participants.
• Novo Nordisk A/S is launching NCT07509307, "AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain." This Phase 3 study will look at the safety and effect of NNC0487-0111, taken as weekly injections, in people with excess body weight and knee osteoarthritis, comparing it to placebo for 400 participants.
• The VA Office of Research and Development is sponsoring NCT07507747, "Testing an Adaptive Intervention for Peer-Supported Mobile Health for Primary Care Veterans With Psychological Distress." This study aims to make services for depression, PTSD, anxiety, and sleep problems more accessible for Veterans through mobile health applications, involving 384 participants.
• Henry Ford Health System is conducting NCT07530172, "Radioembolization Versus External Radiation Therapy." This Phase 2 randomized study will evaluate the efficacy and tolerability of transarterial radioembolization (TARE) versus stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma, involving 146 participants.
• Eli Lilly and Company is sponsoring NCT07533006, "A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)." This Phase 2 study will evaluate how well LY4005130 works in participants with severe alopecia areata (hair loss) when compared with placebo, as well as its tolerability and side effects, for 60 participants.

Expanding Opportunities Across the State

The geographic distribution of new trials this month shows a concentration in Michigan's major metropolitan areas. Ann Arbor and Detroit each saw 6 new trials open, while Troy had 3. Grand Rapids and Ypsilanti also welcomed 1 new trial each. This indicates that while research opportunities are available statewide, the largest number of new studies tend to launch in established research hubs.

New studies are exploring a range of conditions, from common ailments to more specialized areas. This month's new trials are targeting:

• Alopecia areata
• Anticoagulant therapy
• Behavioral symptoms
• Cardiovascular disease and lipoprotein(a)
• Coronary artery disease (CAD)
• Coronary calcification
• Coronary calcified disease
• Coronary calcified nodules
• Differentiated thyroid gland carcinoma

The types of interventions being studied are varied, with drug trials leading the way, accounting for 8 of the new initiatives. Behavioral and device studies each represent 2 new trials, while procedure-based and radiation studies also contribute to the diverse research landscape.

Who Can Participate? Healthy Volunteers and Diverse Demographics

Participation in clinical trials is open to a wide range of individuals. Of the 14 new trials launched this month, 12 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 1 new trial is open to children, and 1 study is specifically designed for male participants. There are no new female-only trials this month.

For individuals without a specific medical condition, there are significant opportunities to contribute. While only 1 of the new trials this month is actively seeking healthy volunteers, across Michigan, a total of 170 clinical trials are currently recruiting healthy participants. These studies are vital for understanding normal physiological responses and comparing them against disease states, providing numerous avenues for those interested in supporting medical research.

Academic institutions continue to play a vital role in Michigan's research ecosystem, with the University of Michigan Rogel Cancer Center sponsoring 3 of the new trials and the University of Michigan sponsoring 2. Industry sponsors, including Eli Lilly and Company, Novartis Pharmaceuticals, Novo Nordisk A/S, and Incyte Corporation, are also driving significant research efforts, accounting for 5 of the new studies this month, alongside other federal and academic initiatives.

As we move further into spring, the focus will likely shift towards the ongoing enrollment in these significant Phase 2 and 3 trials, while researchers prepare for the next wave of innovative studies to address a broad spectrum of health challenges across Michigan.